Some great insights there and statistically significant findings more importantly.
Skin grafts were applied to 39 patients (84.8%) treated with CCS compared with 28 (54.9%) treated with BTM (P =.006); the remaining wounds healing secondarily.
The rate of skin graft failure was significantly higher in the CCS cohort (n = 9 [23.1%]) compared with the BTM group (n = 1 [3.6%]) (P =.006).
More secondary procedures were required after CCS placement (mean ± standard deviation, 1.9 ± 1.8; range, 0-9) than after BTM (mean, 1.0 ± 0.9; range 0-4) (P =.002).
Less rates of skin grafting required, extremely lower rates of graft failure and less secondary procedures required (P<0.05). This is what you want to see when calculating health economics of a medical device! Cheers for the insights KJC.
The Clinicians Speak, page-139
-
- There are more pages in this discussion • 864 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.150(6.61%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.42 | $2.29 | $4.630M | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3536 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 38315 | 8 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |